Oxford BioMedica

Oxford Biomedica (LSE: OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It was established in 1995 as a spin out from Oxford University.[3] The Company’s development pipeline includes investigational treatments for cancer, Parkinson's disease and retinopathy.

Oxford BioMedica plc
Type
Public company (LSE: OXB)
IndustryPharma
Founded1995
Headquarters
Oxford 
,
United Kingdom 
Revenue£15,900,000 (May 2016)[1]
Net income
£−14,100,000 (May 2016)[1]
Number of employees
450[2]
Websitewww.oxb.com

In 2018, Oxford Biomedica's gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences.[4]

Finance

The company had raised a total of £137 million to fund its research and clinical programmes. The IPO on the Alternative Investment Market of the London Stock Exchange in December 1996 raised £5.1 million.

A further £6 million was raised by a rights issue and placing in March/April 1998, £3.6 million by a rights issue in March 1999, £5.2 million in a Placing in January 2000 and £8.8 million in a Placing in August 2000.

Oxford BioMedica's move to the official list of the London Stock Exchange was completed in April 2001 along with a £35.5 million fund raising, before costs, from a placing and open offer.

A Rights Issue for £22.1 million, before costs, was completed in October 2003. A further share offering in December 2005 raised £30.1 million before expenses, including an investment of £2.9 million by Sigma-Aldrich [5]. A placing and open offer in December 2010 raised £20 million.

References
  1. "Annual Report and Accounts 2015" (PDF). Oxford BioMedica. Retrieved 25 December 2016.
  2. "Oxford BioMedica Notes Findings Reported by Novartis on CTL-019 at 58th American Society of Hematology Annual Meeting". Consilium Strategic Communications Limited. 5 December 2016. Retrieved 25 December 2016.
  3. Hoover's | A D&B Company. Hoovers.com.
  4. Cookson, Clive (6 June 2018). "Oxford BioMedica seals $842m Parkinson's therapy deal with Axovant". Retrieved 27 June 2018.
  5. Archived 22 April 2009 at the Wayback Machine
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.